{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Minor response or better assessed by IMWG criteria for multiple myeloma after 8 cycles of therapy with pembrolizumab","groups":[{"description":"Pembrolizumab 200 mg, 30 minute IV infusion every 21 days up to 24 cycles if equal or higher than minor response and without serious adverse events after 8 cycles","id":"OG000","title":"Treatment (Pembrolizumab)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Clinical benefit rate is described as minor response or better assessed by IMWG criteria for multiple myeloma after 8 cycles of therapy with pembrolizumab. 1 participant of 13 achieved sCR","reportingStatus":"POSTED","timeFrame":"From cycle 1 to cycle 8, up to 168 days","title":"Clinical Benefit Rate","type":"SECONDARY","unitOfMeasure":"Participants"}